Physician profile
Emily Pollack
NPI 1619405644
$1,521.08
in general payments reported to CMS, 2019-2025
23 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $380 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $243.57 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $188.63 | 2024-2025 | |
| Lilly USA, LLC | $166.79 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $117.82 | 2024-2025 | Freestyle Libre 3 |
| Insulet Corporation | $112.98 | 2025 | Omnipod |
| Novo Nordisk INC | $111.77 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $87.84 | 2024-2025 | |
| Exact Sciences Corporation | $84.73 | 2024-2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $53.69 | 2025 | Licart, Flector, Tirosint |
| Radius Health, INC. | $47.80 | 2025 | Tymlos |
| Neurocrine Biosciences, INC. | $40.06 | 2025 | |
| Ascendis Pharma Endocrinology INC | $36.79 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $34.09 | 2025 | Recorlev |
| Recordati_rare_diseases_inc. | $33.72 | 2025 | Isturisa |
| Beta Bionics, INC. | $21.78 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $19.70 | 2025 | Twiist |
| Cranial Technologies, INC | $19.15 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $18.51 | 2025 | Gardasil 9, Capvaxive |
| Bavarian Nordic A/S | $17.47 | 2025 | Vivotif |
| Tolmar, INC. | $16.97 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $16.77 | 2024 | Rotarix, Shingrix, Arexvy |
| Ars Pharmaceuticals Operations, INC. | $15.63 | 2025 | Neffy |
| Alexion Pharmaceuticals, INC. | $14.82 | 2025 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.